Alvotech is a privately owned, fully integrated specialty biopharmaceutical company focused exclusively on development and manufacturing of high quality biosimilar products. We are specialists in biogeneric product creation, all along the value chain from cell line development to commercial manufacturing. Our common goal: to be a global leader in the biosimilar space and to deliver high quality cost competitive products to patients worldwide.

We come from all around the world, bringing literally thousands of years of combined knowledge and expertise to our mission.

mAbs in pipeline


CEO message

Alvotech was founded in 2013, with the mission to create a specialty biogeneric’s company focused solely on fully integrated biosimilar product development and manufacturing for global markets.

Learn more


Our growth story

Alvotech was founded in 2013 by the Chairman and CEO of Alvogen, Robert Wessman. Shortly after its creation, Alvotech announced its strategy to invest in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies ...

Learn more


Our vision as a company is to build a leading global biopharmaceutical company, while focusing on the development, and the commercialization of medicines for the treatment of severe, immune, inflammatory conditions.

Our biosimilar assets include six biosimilar monoclonal antibodies that are developed in our four research & development centers located across Europe and will be manufactured in our state-of-the-art facility located in Reykjavik Iceland.

We develop, produce and release our biosimilars in house with the latest available technology and to the highest quality standards for the supply of finished and ready to commercialize products to our partners worldwide

Meet managment


Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.

Meet management


Five key elements

Our strategy is focused on 5 key pillars, incorporated in our culture and in our dailywork. First one is the development of a relevant portfolio of biosimilar mAbs through our fully integrated R&D organization and facilities ...

Learn more
We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.